Difference between revisions of "Altretamine (Hexalen)"
Jump to navigation
Jump to search
m (→Also known as) |
|||
| Line 14: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *12/26/1990: Initial FDA approval | + | *12/26/1990: Initial FDA approval. Indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent [[ovarian cancer]] following first-line therapy with a cisplatin and/or alkylating agent-based combination. |
==Also known as== | ==Also known as== | ||
Revision as of 13:04, 11 September 2019
General information
Class/mechanism: Alkylating-like, exact mechanism unknown—can form covalent adducts with tissue macromolecules including DNA.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Altretamine (Hexalen) patient drug information (Chemocare)[3]
- Altretamine (Hexalen) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/26/1990: Initial FDA approval. Indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.
Also known as
- Generic names: hexamethylmelamine, HMM
- Brand name: Hexalen, Hexastat